Journal Mobile Options
Table of Contents
Vol. 34, No. 4-5, 2005
Issue release date: May 2006
Section title: Paper
Pathophysiol Haemos Thromb 2005;34:169–176
(DOI:10.1159/000092418)

Contortrostatin, a Snake Venom Disintegrin with Anti-Angiogenic and Anti-Tumor Activity

Swenson S.a · Costa F.a · Ernst W.b · Fujii G.b · Markland F.S.a
aUniversity of Southern California, Keck School of Medicine, and bMolecular Express, Inc., Los Angeles, Calif., USA
email Corresponding Author

Francis S. Markland

University of Southern California, Keck School of Medicine

Cancer Research Laboratory #106, 1303 North Mission Road

Los Angeles, CA 90033 (USA)

Tel. +1 323 224 7981, Fax +1 323 224 7679, E-Mail markland@usc.edu


References

  1. Cheresh DA: Structural and biologic properties of integrin-mediated cell adhesion. Clin Lab Med 1992;12:217–236.
  2. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11–25.
  3. Ruoslahti E: Integrins. J Clin Invest 1991;87:1–5.
  4. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569–571.
  5. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815–1822.
  6. Felding-Habermann B, O’Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM: Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001;98:1853–1858.
  7. Huang TF, Holt JC, Kirby ER, Niewiarowski S: Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb-IIIa complex on human platelets. Biochemistry 1989;28:661–666.
  8. McLane MA, Marcinkiewicz C, Vijay-Kumar S, Wierzbicka-Patynowski I, Niewiarowski S: Viper venom disintegrins and related molecules. Proc Soc Exp Biol Med 1998;219:109–119.
  9. Adler M, Lazarus RA, Dennis MS, Wagner G: Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. Science 1991;253:445–448.
  10. Trikha M, Rote WE, Manley PJ, Lucchesi BR, Markland FS: Purification and characterization of platelet aggregation inhibitors from snake venoms. Thromb Res 1994;73:39–52.
  11. Zhou Q, Hu P, Ritter MR, Swenson SD, Argounova S, Epstein AL, Markland FS: Molecular cloning and functional expression of contortrostatin, a homodimeric disintegrin from southern copperhead snake venom. Arch Biochem Biophys 2000;375:278–288.
  12. Trikha M, De Clerck YA, Markland FS: Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res 1994;54:4993–4998.
  13. Zhou Q, Nakada MT, Brooks PC, Swenson SD, Ritter MR, Argounova S, Arnold CA, Markland FS: Contortrostatin, a homodimeric disintegrin, binds to integrin avb5. Biochem Biophys Res Commun 2000;267:350–355.
  14. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA: Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270:1500–1502.
  15. Fujii G, Chang JE, Coley T, Steere B: The formation of amphotericin B ion channels in lipid bilayers. Biochemistry 1997;36:4959–4968.
  16. Swenson S, Costa F, Minea R, Sherwin RP, Ernst W, Fujii G, Yang D, Markland FS Jr: Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol Cancer Ther 2004;3:499–511.
  17. Zhou Q, Sherwin RP, Parrish C, Richters V, Groshen SG, Tsao-Wei D, Markland FS: Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res Treat 2000;61:249–260.
  18. Bao R, Selvakumaran M, Hamilton TC: Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts. Gynecol Oncol 2000;78:373–379.
  19. Zhou Q, Nakada MT, Arnold C, Markland FS: Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis. Angiogenesis 1999;3:259–269.
  20. Markland FS, Shieh K, Zhou Q, Golubkov V, Sherwin RP, Richters V, Sposto R: A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model. Haemostasis 2001;31:183–191.
  21. Golubkov V, Hawes D, Markland FS: Antiangiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom. Angiogenesis 2003;6:213–224.
  22. Shi SR, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741–748.
  23. Newman PJ: The role of PECAM-1 in vascular cell biology. Ann NY Acad Sci 1994;714:165–174.
  24. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolin A, Bevilacqua P, Harris AL: Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. Int J Cancer 1993;55:739–744.
  25. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast cancer. J Natl Cancer Inst 1992;84:1875–1887.
  26. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.
  27. Folkman J: Angiogenesis and breast cancer. J Clin Oncol 1994;12:441–443.
  28. Jain RK: Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29:3–9.
  29. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841–844.
  30. Marx J: Angiogenesis. A boost for tumor starvation. Science 2003;301:452–454.
  31. Nakanishi Y, Kodama J, Yoshinouchi M, Tokumo K, Kamimura S, Okuda H, Kudo T: The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol 1997;16:256–262.
  32. Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K: Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peri toneal dissemination of ovarian cancer. On col Rep 2003;10:89–95.
  33. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287–1295.
  34. Kerbel RS, Klement G, Pritchard KI, Kamen B: Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002;13:12–15.
  35. Dvorak HF: Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog Clin Biol Res 1990;354A:317–330.
  36. Dvorak HF: Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747–1757.
  37. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95–109.
  38. Ruoslahti E: Specialization of tumor vasculature. Nat Rev Cancer 2002;2:83–90.
  39. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363–1380.
  40. Brown JM, Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408–1416.